LBRX · LB Pharmaceuticals Inc
United States · RS rating 82 · As of 2026-10-14
| Price | 34.00 USD |
|---|---|
| 1-day change | -2.3% |
| RS rating (overall / 1M / 3M / 12M) | 82 / 11 / 86 / 96 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 44 / 60 / 45 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +26.2% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +31.3% |
| Market cap (USD) | $882.5M |